PSI CRO presents the changing dynamic of clinical trial feasibility at PCMG meeting

NewsGuard 100/100 Score

PSI CRO, a full-service contract research organization, announced today that Kasia Moscicka, Director Feasibility Research and Patient Recruitment Services, presented on the changing dynamic of clinical trial feasibility at recent PCMG meeting held in Lisbon, Portugal.

To coincide with the 10th anniversary of the PCMG conference, Ms. Moscicka, PSI's Director of Feasibility, gave a fascinating presentation discussing how the feasibility process has evolved over the last 10 years, why conducting thorough feasibility is more important today than it ever was and what we can all learn to ensure we handle the increasing complexity inherent in conducting clinical trial feasibility in a sophisticated and appropriate manner.

During her talk, Ms. Moscicka also presented feedback from a recent survey sent out to industry members to learn more about how different companies approach feasibility studies, what level of control they allow CROs in terms of country/site selection & protocol adaptation, what return on investment do they feel feasibilities provide and what level of accountability for success they expect a CRO to take once they have performed a feasibility and how willing CROs are to do this.

The presentation evoked considerable interest from industry representatives. As inquiries and meeting requests keep arriving following the PCMG talk, be aware that PSI representatives will be available for consultation and further discussion at the upcoming Outsourcing in Clinical Trials UK & Ireland conference to be held on June 25th - 26th at the Royal Garden Hotel, Kensington.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial